Wayne Kelley

Development and Supply at GlaxoSmithKline. He received his doctorate in chemistry from the University of Illinois at Urbana-Champaign under the direction of Jonathan Sweedler performing elucidation and characterization of novel conotoxins and other neurotoxic and neuromodulatory peptide/protein natural products. He has publications in this area including such journals as Biochemistry, Journal of Biological Chemistry, Journal of Neurochemistry and Analytical Chemistry and continues to referee for some of these journals. Dr. Kelley joined GlaxoSmithKline in 2002 as a Principal Scientist in Pharmaceutical Development. He won several scientific awards including recognition for achievements towards furthering understanding of oral peptide delivery for related projects. He also served as an analytical lead (including two NDA approvals; Altabax® and Promacta®) and CMC project leader for programs including PHI and Gro Beta. In late 2008, Wayne moved to Biopharmaceutical R&D and took the role of revising and strengthening analytical method development strategies including implementing platform method development. He also revised the biopharmaceutical product specification development and approval process and continues to lead the BioPharm Specification Board. He was awarded Fellow in the GSK society of Fellows in 2016. His current role also includes due-diligence activities and late phase project representation (analytical/QC).